Quotient Limited, Iovance Biotherapeutics and AVEO Pharmaceuticals are among the names seeing insider purchases.
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
Daniel O'Day will take over the helm of the biopharmaceutical giant on March 1, 2019.
It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.
Shares decline after the company says a lung-cancer study it had been working on failed.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.